snIP/ITs Insights on Canadian Technology and Intellectual Property Law

Monthly Archives: July 2012

Recent Pair of Rampiril Decisions Clarifies Limits on s. 8 Damages in Patent Law

Posted in Intellectual Property, Patents

When a generic drug claims damages against a brand name drug, what limits should be put on calculating compensation? Section 8 of the Patented Medicines (Notice of Compliance) Regulations was designed to answer just that question, but it left some questions unanswered. A pair of twin judgments by Justice Snider, Teva Canada Ltd. v. Sanofi-Aventis… → Read More

Responding to Canadian Patent Office Objections: Dosing Regimens

Posted in Intellectual Property, Patents

This is part of a series of posts reviewing common Canadian Patent Office objections to patent applications and claimed inventions and providing some insight into how these objections may be addressed. The Objection In a typical objection, the patent examiner asserts that the claimed medical treatment with dosing elements is unpatentable subject matter falling outside… → Read More